82/100 · Critical
Manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
High Safety Concerns with Estrogens, Conjugated: Breast Cancer and Cardiovascular Risks
102,186 FDA adverse event reports analyzed
Last updated: 2026-05-12
ESTROGENS, CONJUGATED is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. Based on analysis of 102,186 FDA adverse event reports, ESTROGENS, CONJUGATED has a safety score of 82 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for ESTROGENS, CONJUGATED include BREAST CANCER, BREAST CANCER FEMALE, DRUG INEFFECTIVE, NAUSEA, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ESTROGENS, CONJUGATED.
Estrogens, Conjugated has a safety concern score of 82 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 102,186 adverse event reports for this medication, which is primarily manufactured by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc..
The most commonly reported adverse events include Breast Cancer, Breast Cancer Female, Drug Ineffective. Of classified reports, 71.1% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Serious adverse events, particularly breast cancer and cardiovascular issues, are prevalent.
A significant number of reports involve drug ineffectiveness and off-label use. Common non-serious reactions include nausea, headache, and fatigue.
Patients taking Estrogens, Conjugated should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Caution is advised with concomitant use of other drugs that may increase the risk of thrombosis or cardiovascular events. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Estrogens, Conjugated received a safety concern score of 82/100 (high concern). This is based on a 71.1% serious event ratio across 58,742 classified reports. The score accounts for 102,186 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 56,218, Male: 205, Unknown: 101. The most frequently reported age groups are age 59 (1,138 reports), age 57 (1,119 reports), age 62 (1,102 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 58,742 classified reports for ESTROGENS, CONJUGATED:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Caution is advised with concomitant use of other drugs that may increase the risk of thrombosis or cardiovascular events.
If you are taking Estrogens, Conjugated, here are important things to know. The most commonly reported side effects include breast cancer, breast cancer female, drug ineffective, nausea, headache. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Discuss any concerns about the effectiveness of the medication with your healthcare provider. Be aware of potential side effects and report any unusual symptoms promptly. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Regulatory oversight is ongoing, with a focus on monitoring and managing risks associated with breast cancer and cardiovascular outcomes.
The FDA has received approximately 102,186 adverse event reports associated with Estrogens, Conjugated. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Estrogens, Conjugated include Breast Cancer, Breast Cancer Female, Drug Ineffective, Nausea, Headache. By volume, the top reported reactions are: Breast Cancer (9,639 reports), Breast Cancer Female (8,870 reports), Drug Ineffective (3,402 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Estrogens, Conjugated.
Out of 58,742 classified reports, 41,779 (71.1%) were classified as serious and 16,963 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Estrogens, Conjugated break down by patient sex as follows: Female: 56,218, Male: 205, Unknown: 101. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Estrogens, Conjugated adverse events are: age 59: 1,138 reports, age 57: 1,119 reports, age 62: 1,102 reports, age 61: 1,068 reports, age 58: 1,057 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Estrogens, Conjugated adverse event reports is Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Estrogens, Conjugated include: Pain, Fatigue, Off Label Use, Breast Cancer Metastatic, Dizziness. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Estrogens, Conjugated to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Estrogens, Conjugated has a safety concern score of 82 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Serious adverse events, particularly breast cancer and cardiovascular issues, are prevalent.
Key safety signals identified in Estrogens, Conjugated's adverse event data include: High incidence of breast cancer and its metastatic forms.. Multiple cardiovascular events, including myocardial infarction and deep vein thrombosis.. Significant reports of drug ineffectiveness and off-label use.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Caution is advised with concomitant use of other drugs that may increase the risk of thrombosis or cardiovascular events. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Estrogens, Conjugated.
Discuss any concerns about the effectiveness of the medication with your healthcare provider. Be aware of potential side effects and report any unusual symptoms promptly.
Estrogens, Conjugated has 102,186 adverse event reports on file with the FDA. A significant number of reports involve drug ineffectiveness and off-label use. The volume of reports for Estrogens, Conjugated reflects both the drug's usage level and the vigilance of the reporting community.
Regulatory oversight is ongoing, with a focus on monitoring and managing risks associated with breast cancer and cardiovascular outcomes. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. and compare their safety profiles:
View all Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. drugs →
The following drugs share commonly reported adverse reactions with ESTROGENS, CONJUGATED:
Drugs related to ESTROGENS, CONJUGATED based on therapeutic use, drug class, or shared indications: